Every patient treated for rectal cancer with an experimental immunotherapy drug went into remission, in findings that researchers have hailed as a breakthrough.
All 14 patients who were given the new drug, dostarlimab, were found after six months to have no trace of cancer. Researchers at Memorial Sloan Kettering cancer center in New York could find no sign of the disease through physical examination, endoscopies, MRIs or other scans.
The researchers described the results, published in the New England Journal of Medicine, as “breakthrough findings” and said they were astonished by the universal success rate. “I believe this is the first time this has happened in the history of cancer,” Dr Luis Diaz, a leading member of the team, told the New York Times.
Rectal cancer: researchers hail ‘breakthrough’ experimental treatment | Cancer research | The Guardian